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Abstract
Despite improved outcomes in the past 30 years, less than half of all women diagnosed with epithelial ovarian cancer live
five years beyond their diagnosis. Although typically treated as a single disease, epithelial ovarian cancer includes several
distinct histological subtypes, such as papillary serous and endometrioid carcinomas. To address whether the morphological
differences seen in these carcinomas represent distinct characteristics at the molecular level we analyzed DNA methylation
patterns in 11 papillary serous tumors, 9 endometrioid ovarian tumors, 4 normal fallopian tube samples and 6 normal
endometrial tissues, plus 8 normal fallopian tube and 4 serous samples from TCGA. For comparison within the endometrioid
subtype we added 6 primary uterine endometrioid tumors and 5 endometrioid metastases from uterus to ovary. Data was
obtained from 27,578 CpG dinucleotides occurring in or near promoter regions of 14,495 genes. We identified 36 locations
with significant increases or decreases in methylation in comparisons of serous tumors and normal fallopian tube samples.
Moreover, unsupervised clustering techniques applied to all samples showed three major profiles comprising mostly normal
samples, serous tumors, and endometrioid tumors including ovarian, uterine and metastatic origins. The clustering analysis
identified 60 differentially methylated sites between the serous group and the normal group. An unrelated set of 25 serous
tumors validated the reproducibility of the methylation patterns. In contrast, .1,000 genes were differentially methylated
between endometrioid tumors and normal samples. This finding is consistent with a generalized regulatory disruption
caused by a methylator phenotype. Through DNA methylation analyses we have identified genes with known roles in
ovarian carcinoma etiology, whereas pathway analyses provided biological insight to the role of novel genes. Our finding of
differences between serous and endometrioid ovarian tumors indicates that intervention strategies could be developed to
specifically address subtypes of epithelial ovarian cancer.
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Introduction
Ovarian cancer has an incidence of 21,500 cases per year in the
United States and 204,000 worldwide, with an estimated annual
mortality of 125,000 women. The condition ranks as the 5th
leading cause of cancer-related deaths for women in the United
States; the high mortality rate is a consequence of the
asymptomatic nature of early-stage disease and the absence of a
reliable screening test. The majority of cases (75%) are diagnosed
at an advanced stage (III or IV) wherein the 5-year survival rate is
less than 30% [1].
Of the four major histopathologic subtypes, serous is the most
common, followed by endometrioid, mucinous and clear cell
types. These subtypes have distinctive gene expression profiles [2]
and are classified by virtue of their morphologic resemblance to
normal fallopian tube, endometrium, endocervix and endometrial
clear cells, respectively [3]. The resemblance between tumor
subtypes and distant tissues is consistent with models that propose
migration of precursor lesions from disparate origins, such as the
fallopian tube [4] or the mesothelial covering of the peritoneal
cavity [5]. For this reason, ovarian serous tumors (which resemble
Mullerian epithelia) can be legitimately compared to normal
fallopian tube (which is derived from Mullerian epithelia).
Nevertheless, the ovarian surface epithelial (OSE) layer [6] shares
its origin with epithelia of the endometrium (known as celomic
epithelium [7]) and remains a plausible alternative explanation for
‘‘de novo’’ tumorigenesis.
Like serous tumors, the origin of endometrioid tumors is
controversial [8], and progenitor cells have been proposed to
originate from non-ovarian sources, such as endometriosis [9].
Tumors with endometrioid histopathology are diagnosed in both
the uterus and ovary. They frequently co-occur, as synchronous
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primary tumors or metastases from uterus to ovary [10]. Whereas
molecular differences have been reported for dual primary tumors,
metastatic tumors are clonally identical [11].
Gene expression studies of ovarian tumors intended to detect
cancer-specific profiles have yielded modest success and limited
reproducibility [12,13,14,15]. However, mutational profiling
studies have yielded more consistent results, showing that both
serous and endometrioid tumors have aggressive, high-grade
subtypes [16,17,18] with mutations in the TP53 gene [19,20,21]
despite their obvious histological differences [16,17,18]. Low-
grade subtypes are most common in endometrioid tumors with
mutations predominantly occurring in WNT and PIK3CA
pathways [2].
In concert with gene expression and mutational profiles,
delineating the epigenome of tumor cells should reveal relation-
ships among samples reflecting common embryological origins,
similar histopathological outcomes, or shared mutational events.
In ovarian tumors, DNA methylation silences expression of critical
genes [22,23], and creates genetic haploinsufficiency [24], while
hypomethylation at other sites enables expression of normally
silenced genes. As proof of principle, site-specific patterns of DNA
methylation were recently used to distinguish four subtypes of
epithelial ovarian cancers, using a total of 1,505 target CpG loci
[25,26].
We hypothesized that DNA methylation patterns in ovarian
tumors would resemble cells from their putative tissue of origin,
with a small number of changes representing events associated
with malignancy, that uniquely represent each tumor subtype.
Moreover, we also hypothesized that uterine and ovarian
endometrioid tumors were related by pathogenic mechanisms,
which would be observed in DNA methylation patterns. To
address these ideas, we examined methylation profiles of 27,578
target CpG sites representing 14,495 genes in the human genome,
using DNA derived from serous and endometrioid ovarian tumors,
normal fallopian tube and normal endometrium, and primary and
metastatic endometrioid endometrial tumors. This large dataset
was analyzed using a supervised analysis followed by de novo
classification using unsupervised computational clustering. To
improve the strength of the epigenetic profiling technique, we
included raw methylation data from serous tumors and normal
fallopian tube generated through The Cancer Genome Atlas
(TCGA). These samples were analyzed using the same methyla-
tion platform, and performed by independent research laborato-
ries using independent tumor specimens.
Results
Experimental assay and design
We analyzed the DNA methylation status of genomic samples
using the Illumina Infinium platform. DNA was treated with
bisulfite to convert unmethylated cytosines to uracil, leaving
methylated cytosines unchanged. The hybridization reaction on
the HumanMethylation27 Illumina BeadChip provided signal
specific to the methylated and unmethylated states, using the
Illumina single base extension assay protocol [27]. The differential
hybridization of probes to methylated and unmethylated target
sites was tabulated as the fraction of the total signal that
corresponded to the methylated state. The initial sample set
represented various tissue and tumor types including normal
fallopian tube, normal endometrium, ovarian papillary serous
carcinoma, ovarian endometrioid carcinoma, and primary and
metastatic endometrial endometrioid carcinoma from 42 patients
(Table 1). Technical replicates indicated highly reproducible
results for the assay (Figure S1). In addition, we included data
from the same Illumina methylation platform for 12 additional
samples from the public database of The Cancer Genome Atlas
project (TCGA). This set comprised 8 control samples (normal
fallopian tube) and 4 tumor samples (ovarian serous), contributed
in a single batch of samples examined under consistent
experimental conditions from one data provider.
Bulk methylation
To assess gross changes in degree of methylation, we examined
aggregate methylation levels of all samples. Assay values are
reported as the proportion of fluorescence arising from the probe
for the methylated state, from 0 (all DNA unmethylated) to 1 (all
DNA methylated). Comparing all samples, the vast majority
showed consistent methylation profiles. Across the genome, most
assayed sites had methylation levels between 0 and 0.2, small
numbers of sites had levels between 0.2 and 0.8, and a slightly
larger number had levels of 0.8 to 1 (Figure 1).
In contrast, considering only the X-chromosome, single-copy
silencing by random X-inactivation was expected to produce a
methylation level of 0.5. The observed pattern showed a broad
peak centered at 0.5 for most samples, even though the tumor
samples had more extensive heterogeneity. Five serous tumor
samples showed a distinct profile, with many loci being
unmethylated (i.e., methylation level ,0.2), indicating either a
failure to maintain X-inactivation or copy number alterations with
Table 1. Experimental samples for data clustering and validation testing.
Sample Type Non-cancerous
Stage
1
Stage
2
Stage
3–4
Fallopian tube 4
Endometrium 6
Serous tumor 3 4 5
Ovarian endometrioid tumor 5 2 2
Endometrial endometrioid tumor, validation set 6
Ovarian metastases of endometrial tumor 5
TCGA Fallopian tube normal 8
TCGA serous tumor 4
Serous tumor, validation set 25
doi:10.1371/journal.pone.0032941.t001
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relative excess of the active X [28]. To assess whether this
observed variation was simply due to the small number of loci on
the X-chromosome, we also considered methylation levels on
chromosome 10, which had a similar number of probes. The
pattern for chromosome 10 resembled the pattern across all
autosomal loci, with high levels of similarity from sample to
sample.
Supervised analysis
We first considered whether the tumor subtypes (defined by
histopathology) corresponded to specific methylation profiles.
With the inclusion of the TCGA samples, 12 normal fallopian
tube samples and 16 ovarian serous tumors yielded sufficient
statistical power for a direct comparison. Probes with poor quality
control, high variability in the controls, or located on X or Y-
chromosomes were not considered (see Methods). Using a
Wilcoxon summed-rank test to identify sites that consistently
associated with prior classification, 36 were significant at p,0.05
after multiple-testing correction (14 at p,0.01; Table 2). Three
genes were identified as members of the canonical pathway for
ovarian cancer in an Ingenuity Pathway Analysis (IPA) (Table 2;
[29] [30] [31] [32]). Supervised analysis of the ovarian
endometrioid tumors against the fallopian tube or endometrial
controls was not performed due to small numbers of samples.
Unsupervised clustering
To address whether other sample divisions with shared
molecular phenotypes existed and to gain a broader picture of
the relationships between the sample types, we moved to
unsupervised clustering. Utilizing the complete set of 31 primary
tumor samples and 18 normal tissues (and excluding the 5
metastatic samples used for secondary analysis), we limited this
analysis to probes that were in the top 500 when ranked by
variance, as reported by Houseman et al. [33] to reduce the
dimensionality of the data. Results of multiple clustering
algorithms converged on the same interpretation of distinct
phenotypic groups (Figure S2). K-means clustering and partition-
ing using a b-mixture model designed for the data from this
platform [33] both strongly supported the existence of 3 primary
groups, roughly corresponding to control-type samples, serous
tumor-type samples, and endometrioid samples. Additional
analysis with hierarchical clustering (across multiple distance
metrics and linkage methods) strongly supported the control-type
and endometrial type clusters, and indicated the serous tumor-type
samples were an outgroup from the control samples, but was
inconsistent as to whether these samples formed a distinct
subgroup (Figure S2).
The consensus groupings, as shown in Figure 2, are marked
with a colored bar to indicate the normal-type, serous-type or
endometrioid-type. Notably, the control group contained normal
fallopian tube and normal endometrium, indicating a consistent
phenotype across both tissues within the set of featured probes.
The TCGA samples clustered with their identified sample types,
confirming the reproducibility and robustness of the results as
these tumors were obtained and classified at various institutions.
Exclusion of the TCGA samples from the analysis had relatively
small impact on the results, in which a marked division remained
between the endometrioid and serous or control samples; however,
only weak support remained for a subdivision of the serous-type
tumors from the control samples.
The cluster of endometrioid samples, including tumors from
both ovarian and uterine sites, displays a remarkably altered
profile, with methylation at numerous sites that are normally
unmethylated CpG islands, and a loss of methylation at sites that
are normally methylated. The extent and reproducibility of these
changes is strongly reminiscent of the methylator phenotypes
noted in other cancers [34] [35]. A methylator phenotype has
previously been proposed for endometrial endometrioid carcino-
ma, based on methylation of promoters of a few target genes [36],
but has not to our knowledge been described in a genome-level
survey or in ovarian cancer.
These data confirm the hypothesis that endometrioid type
tumors, whether at ovarian or uterine sites, share similarities at the
molecular level. To further address this finding, we analyzed five
ovarian metastases derived from primary endometrial tumors
using a nested log-likelihood-ratio test. This test addressed
consistency of clustering with the primary endometrioid samples
versus the combined serous tumors and controls, and secondarily
enabled classification within the serous or control groups when
necessary. Four of the five samples were strongly identified as
endometrioid-type, whereas the fifth was more similar to the
control samples (sample 54; Figure 2). The fifth sample does not
Figure 1. Bulk methylation levels across genomic loci. Frequency of methylation at all loci for a given level of methylation (range 0 to 1). Each
biological sample is represented as a single line; all non-metastatic samples were plotted. Respectively, panels from left to right contain all loci
(N = 27,561), X chromosome only (N = 1038), or chromosome 10 only (N = 1044).
doi:10.1371/journal.pone.0032941.g001
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appear grossly altered from the methylation of normal endometrial
tissue, indicating that the majority tumor phenotype is not
universal. This outlier may represent an uncommon subdivision
of endometrioid tumors, resulting from different underlying
pathology, however it does not represent a low-grade tumor
(Figure 2).
Assessment of primary tumors of all histopathologies also
identified infrequent outliers. Examples included endometrial
endometrioid samples 47 and 49, which clustered with normal
tissues and contributed to the 15% of samples that showed
discordant placement relative to their assigned histopathology
(grade 1 and grade not available, respectively; Figure 2). Four
ovarian serous tumors also clustered with normal tissues, showing
very limited changes in methylation relative to controls (grades 2
and 3). Given the phenotypic similarity of these samples to normal
controls, the biological underpinning of this tumor subset requires
further investigation. Additionally, one ovarian endometrioid
sample grouped with the serous tumors (sample 36, grade 2),
suggesting either a rare endometrioid subtype with a more
aggressive, serous-like profile, or mistyping of a poorly differen-
tiated sample.
Differential analysis of clusters
Given the three primary groupings provided by the unsuper-
vised clustering analysis, we wished to identify methylation loci
most predictive of membership in a particular class. We repeated
the Wilcoxon summed-rank test used in the supervised analysis,
after removing from consideration the 500 probes used in
clustering. Comparing the serous-type cluster with the control-
type cluster, 35 probes remained significant at p,0.01 after
stringent Bonferroni correction for multiple tests and 60 remained
at p,0.05 (Table 3). The results showed a mixture of hyper- and
hypomethylation relative to the controls (Figure S3). An IPA
analysis identified known biomarkers for ovarian cancer among
this list (Figures S4 and S5). Two genes with recorded relevance to
DNA methylation were identified, including DNMT3A, a DNA
methyltransferase gene and RB1. APC (from the beta-catenin
pathway), RBAK1 (an RB1 interaction partner), MAPK15 and
MAP2K2 kinases, and histone deacetylase HDAC1 were also on the
list (Table 3). Although the supervised and unsupervised analyses
utilized different comparator sets, the gene lists contained 10
overlapping entries (Table 3).
Considering the endometrioid-cluster versus the control cluster,
we determined that the number and degree of differentially
methylated sites increased by more than an order of magnitude.
For example, 954 probes were significant at p,0.01. The sheer
number of hypermethylated sites suggests an underlying defect in
DNA methylation pathways, and limits the utility of considering
altered methylation of individual genes.
Validation of differential methylation
To explore whether our set of 60 differentially methylated sites
in serous tumors was reproducible, we assessed the methylation of
25 additional samples that were independent of the original
analysis set. All were typed as ovarian serous carcinoma and
analyzed independently (independent in ascertainment and in time
of analysis) from the originals. For each site and for each validation
sample, we assessed whether the methylation more closely
resembled the normal sample cluster or the serous tumor sample
cluster. Of the 25 tumor samples, 4 closely resembled the
methylation pattern of normal samples, seven were altered at 21
or more of the 60 loci, and 14 samples showed the altered pattern
at 40 or more of the 60 loci (Figure 3).
Evaluation of published methylation events
Our analysis of differential methylation focused on changes that
defined characteristics of each group and were shared among all or
nearly all samples. Many important changes in methylation state,
previously reported in the literature, have lower prevalence and
are not directly identified by our approach. When we assessed our
samples for patterns of known methylation, our data were
consistent with published results. For instance, BRCA1 was
hypermethylated in 2 of 16 (12.5%) of ovarian serous samples.
The tumor suppressor RASSF1A showed evidence of complete
methylation in 11 tumors, and single-copy methylation in 4 more
(31% of serous, and 60% of endometrioid). These changes, and
Table 2. Differential methylation of genes in supervised
analysis, p,0.05.
Gene Chr Pos
Control
Median
Serous
Median P-value Probe
HSPA2 14 64075923 0.25 0.08 0.0016 cg01520924
CLIC3 9 139010829 0.18 0.06 0.0016 cg02189785
CBFB 16 65620188 0.26 0.10 0.0016 cg06766367
FAM3C 7 120823965 0.31 0.17 0.0016 cg14175438
PIP5K2C 12 56270986 0.15 0.07 0.0016 cg25133016
CHAC1 15 39032145 0.86 0.77 0.0016 cg26065841
XLF 2 219733988 0.26 0.16 0.0033 cg04587910
SPINT2* 19 43446608 0.14 0.06 0.0033 cg13301014
SNTB1 8 121894651 0.83 0.36 0.0033 cg14992108
LOC387882 12 104249242 0.13 0.06 0.0033 cg26940261
PARP3 3 51951707 0.71 0.43 0.0066 cg12554573
DSCR6 21 37299808 0.83 0.91 0.0066 cg12564962
EIF4E 4 100070234 0.29 0.10 0.0066 cg15633390
MRGPRX4 11 18149936 0.59 0.36 0.0066 cg16446783
LGP1 17 37600206 0.25 0.10 0.012 cg08468689
PDPK1 16 2527081 0.80 0.44 0.012 cg14444710
PTGES* 9 131555630 0.76 0.59 0.012 cg17683775
MGC4399 1 9521654 0.82 0.73 0.012 cg18783781
CD58 1 116914377 0.27 0.09 0.012 cg21039631
FLJ00060 19 59739533 0.80 0.51 0.02 cg03602500
CDKN3 14 53933994 0.13 0.05 0.02 cg03724882
GIT1 17 24941283 0.31 0.17 0.02 cg05379350
PLEKHF1 19 34847706 0.49 0.26 0.02 cg05512099
DPP8 15 63597257 0.11 0.04 0.02 cg06993413
FLJ22555 2 200527315 0.77 0.56 0.02 cg15761233
CSRP3 11 19180211 0.72 0.43 0.02 cg19216731
HDAC1* 1 32529881 0.37 0.20 0.02 cg24468890
HUNK 21 32166623 0.16 0.07 0.02 cg25048564
SOCS3 17 73866797 0.25 0.02 0.02 cg27637521
ZNF154 19 62912474 0.09 0.56 0.031 cg08668790
FGF18* 5 170778215 0.62 0.47 0.031 cg15699524
S100A8 1 151630204 0.44 0.15 0.031 cg24898863
TLCD1 17 24076955 0.14 0.05 0.049 cg07195577
C7orf34 7 142346962 0.25 0.13 0.049 cg10896774
NFYB 12 103056507 0.21 0.12 0.049 cg10954182
DNAJC14 12 54509148 0.22 0.12 0.049 cg11380624
*appears in IPA canonical pathway for ovarian cancer.
doi:10.1371/journal.pone.0032941.t002
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others, are likely to be important transformative events, but are
restricted to smaller subsets of the samples.
Gene ontology & pathway analyses
To tie these results to the literature on ovarian cancer, we
performed a gene ontology (GO) analysis and an IPA analysis of
the differentially methylated genes from the cluster-based
comparison of serous tumors versus controls. The genes
corresponding to the methylated loci in our list showed a
statistically significant enrichment for GO terms involving
regulation of cell cycle (Table 4). The top two networks identified
by IPA included ‘‘Cell Cycle and Cell Morphology’’ and
‘‘Inflammatory Response’’ with network scores of 24 and 23,
respectively. The network score is based on a hypergeometric
distribution and is calculated with the right-tailed Fisher’s Exact
Test, implying that there is a 1 in 1023 or 1024 probability of either
network occurring from a random list of genes (Table 4, Figure
S4,S5). Notably, differentially methylated genes had a large
Figure 2. Methylation status at top 500 most variable probes. Heatmap of methylation levels; blue = 0.0, black = 0.5, yellow= 1.0. At left, a
representative sample of hierarchical clustering, and color blocks giving the consensus groups. Six columns on the right give sample characteristics:
number; tumor (T) or normal (N); location in ovary (O), fallopian tube (F), or endometrium (E); histology of serous (S) or endometrioid (O); grade (1–3;
where symbols used are ‘-’ for normals and ‘NA’ for information not available.) and at far right, dots for public TCGA data. Five samples at bottom are
ovarian metastases from endometrial endometrioid tumors, excluded from the initial analysis and clustering.
doi:10.1371/journal.pone.0032941.g002
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Table 3. Differential methylation of genes in cluster-based analysis, p,0.05.
Gene Chr Pos
Control
Median
Serous
Median P-value Probe
IPA
Network
RBAK 7 5051647 0.27 0.51 5.6e-05 cg06914598 1
MOS 8 57188855 0.10 0.34 9.9e-05 cg22411207 1
GSTP1 11 67107075 0.81 0.41 0.00016 cg05244766 1
PLEKHF1* 19 34847706 0.49 0.24 0.00027 cg05512099
MAPK15 8 144869951 0.74 0.46 0.00027 cg11695358 2
FLJ22555* 2 200527315 0.73 0.52 0.00027 cg15761233
HTATIP2 11 20341661 0.53 0.29 0.00027 cg18788940
S100A8* 1 151630113 0.51 0.20 0.00027 cg20070090 2
AHR 7 17304501 0.55 0.24 0.00042 cg13676215 1
NNAT 20 35583164 0.65 0.86 0.00042 cg23566503
IL6 7 22732680 0.20 0.10 0.00063 cg01770232 2
LGP1* 17 37600206 0.22 0.08 0.00063 cg08468689
OR10J1 1 157675831 0.52 0.25 0.00065 cg15700197
PDPK1* 16 2527081 0.77 0.36 0.00094 cg14444710 1
GPR123 10 134734167 0.54 0.28 0.00094 cg21607649 2
CCT6A 7 56085732 0.56 0.25 0.00094 cg23839680 1
FLJ00060* 19 59739533 0.82 0.43 0.0014 cg03602500
BTNL2 6 32482732 0.68 0.32 0.0014 cg25391023 2
S100A8 1 151630204 0.43 0.12 0.002 cg24898863 2
ZNF540 19 42733963 0.23 0.47 0.002 cg27389185
LILRA5 19 59516087 0.40 0.26 0.0027 cg06392096
PARP3* 3 51951707 0.67 0.39 0.0027 cg12554573
MAP2K2 19 4074852 0.16 0.30 0.0027 cg24748945 1
AIF1 6 31691437 0.16 0.34 0.0038 cg21440587 2
WBP11 12 14848787 0.65 0.43 0.0038 cg22833175
CYP4F11 19 15906788 0.39 0.18 0.0053 cg03190825
FLJ44674 16 47935998 0.78 0.40 0.0053 cg13897627
DPP6 7 154059965 0.69 0.40 0.0053 cg26738880
MGC15523 17 76884479 0.46 0.22 0.0071 cg00466249
PRAME 22 21231596 0.47 0.27 0.0071 cg05208878 2
RB1 13 47793174 0.51 0.65 0.0071 cg19254235 1
DCAKD 17 40495243 0.53 0.31 0.0096 cg09214551
MRGPRX4* 11 18149936 0.59 0.33 0.0096 cg16446783
KPNA1 3 123716824 0.15 0.05 0.0096 cg25564800
LOC126248 19 38314931 0.58 0.84 0.0096 cg26687173
M-RIP 17 16886972 0.35 0.53 0.013 cg02889982
CACNG3 16 24173204 0.68 0.40 0.013 cg04721098
CBFB* 16 65620188 0.26 0.10 0.013 cg06766367
C1QC 1 22841927 0.33 0.11 0.013 cg11393848
INSL4 9 5221360 0.81 0.55 0.013 cg19297688 2
APC 5 112101585 0.07 0.10 0.013 cg24332422
MYH1 17 10360224 0.74 0.49 0.017 cg00134787
LUC7L 16 220047 0.70 0.49 0.017 cg07080946
KRTAP13-4 21 30724700 0.71 0.47 0.017 cg14062083
C18orf37 18 31332717 0.85 0.76 0.017 cg27318281
C11orf38 11 125154608 0.53 0.30 0.022 cg07747336
CCDC47 17 59203744 0.44 0.18 0.022 cg20131968
DNAJC14* 12 54509148 0.21 0.09 0.029 cg11380624
NFS1 20 33752164 0.90 0.85 0.029 cg14963897
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presence in these networks, interacting with important genes in
ovarian tumor development including AKT, PI3K, VEGF, and
estrogen receptor.
Discussion
This work represents one of the largest studies of methylation
using several normal and tumor subtypes of gynecologic cancers.
We initially examined the methylation status of 27,578 sites for 49
samples including normal fallopian tube and endometrium, serous
ovarian cancer, endometrioid ovarian cancer, primary endome-
trioid endometrial cancer, and ovarian metastasis of endometrial
cancer. Regardless of tumor or normal status, all samples showed
similar profiles in the overall distribution of methylated sites.
Although we did not find global shifts toward hyper- or
hypomethylation across the assayed samples, a subset of samples
showed drastically altered methylation for the X chromosome,
consistent with loss of the inactive X chromosome, amplification of
the remaining active X, or both [28]. Examples of aneuploidy,
including the autosomes, are common in high-grade serous
ovarian cancer and are not directly ascertained by this analysis,
but influence the proportional methylation levels at each locus.
Therefore we removed all probes on the X-chromosome from our
dataset.
Our data confirm that different histological subtypes have
distinct patterns of methylation. Moreover, ovarian serous tumors
are more similar to normal ovarian and endometrial tissues than to
ovarian or endometrial endometrioid tumors, which are highly
similar to each other and display drastic and consistent changes in
their methylation. This result is consistent with a methylator
phenotype and in agreement with a model of ovarian endome-
trioid tumors arising from endometriosis, where the cells ultimately
derive from a uterine lineage. Endometrioid tumors from the
ovary and uterus share several common somatic mutations [6],
and these data support a similar pathogenic mechanism. The
marked differences in methylation profiles between histological
subtypes underscore the importance of characterizing tumors at
the molecular level in order to develop tailored treatment
strategies.
For the identification of differentially methylated loci, we used
known labels and blinded (data-directed) subgroups. Known labels
identified a few dozen genes, some with characterized roles in
ovarian cancer. However, given the stringent bar for statistical
significance in testing very large numbers of sites, we found that a
few outliers within a group could obscure important patterns. By
clustering data in an unbiased approach, we found similar
methylation patterns among normal samples and some tumor
outliers, indicating that current histologic subtyping strategies may
miss important molecular distinctions between tumors. This point
was further supported in metastatic endometrioid tumors, which
also contained an outlier that looked like a normal sample in its
methylation patterns. Our clustering approach clearly identified a
set of 500 genes that could separate the majority of serous samples
from endometrioid samples and normal controls. Although the
clustering was distinctive for the three main classes of samples, its
use precluded a statistical evaluation of the significance of genes
within the set. Nevertheless, the increased power of clustering 49
samples identified an additional 60 loci that were independent of
the clustering set and segregated samples into normal or serous
Table 3. Cont.
Gene Chr Pos
Control
Median
Serous
Median P-value Probe
IPA
Network
DNMT3A 2 25419299 0.74 0.57 0.029 cg21629895 1
LOC284739 20 62139546 0.40 0.25 0.029 cg22940152
PTAFR 1 28375495 0.76 0.60 0.029 cg24354652 2
ANKMY2 7 16653296 0.38 0.17 0.037 cg25778479
TXNL4A 18 75850362 0.73 0.51 0.048 cg02955504
PCDHGA12 5 140790321 0.21 0.60 0.048 cg07730329
EDG4 19 19600820 0.34 0.13 0.048 cg10521852
STRN3 14 30566605 0.77 0.46 0.048 cg15301694 1
DCC 18 49292066 0.79 0.72 0.048 cg18572014 1
FGF22 19 591346 0.60 0.41 0.048 cg22189019
UNC5CL 6 41115500 0.78 0.56 0.048 cg22346765 1
1= IPA network for Cell Cycle and Cell Morphology, 2 = IPA network for Inflammatory Response.
*appears in supervised and unsupervised lists.
doi:10.1371/journal.pone.0032941.t003
Figure 3. Classification of 25 additional serous tumors.
Methylation at 60 loci was used to evaluate an independent set of
serous tumors. Each row represents an individual sample; each column
corresponds to one of the previously identified differentially methylated
sites. An empty box indicates methylation more similar to the control
cluster (not necessarily unmethylated); a filled black box indicates
methylation more similar to the cluster of ovarian serous tumors.
Samples are ordered by the number of sites having methylation
resembling the serous tumor group.
doi:10.1371/journal.pone.0032941.g003
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subtypes with statistical significance. Several of these genes
correspond to networks implicated in the development of ovarian
cancer (Figures S4 and S5). We investigated the overlap between
gene lists of statistically significant genes identified in the
supervised and unsupervised approaches and found 10 genes.
Notably, the kinase PDPK1 is in the PI3K signaling pathway
involved in serous ovarian cancer [37]. PDPK1 and PLEKHF1
share a pleckstrin homology domain, capable of binding inositol
polyphosphates. PARP3 is involved in DNA repair and genome
stability. Given the reproducible signal from these genes regardless
of method, we conclude that uncharacterized genes in this list are
strongly implicated in ovarian tumor development and require
additional characterization.
A limitation of our analysis is that we did not screen the tumor
DNA for gene mutations or ascertain gene expression levels;
nevertheless, we found that RB1 and RBAK are differentially
methylated between the papillary serous and normal fallopian tube
samples. RB1 was recently reported by TCGA to be involved in
serous tumor etiology, through mutation or deletion in 67% of
tumors [38]. The involvement of the RB1 pathway is consistent
with concurrent Rb1 and Tp53 mutation in mice, which simulates
characteristics of aggressive serous ovarian cancers, including
formation of ascites and metastasis [39]. Although we did not find
significant overlap with the list of methylated genes in serous
tumors published by TCGA, this discordance may be due to
methodological issues. For example, we do not limit the gene list to
candidates that become hypermethylated and found many that
lose methylation. Furthermore, we required that scoring be
consistent among all tumors. TCGA limits scoring to the top
10% of tumors. Additionally, we did not limit results to genes that
become silenced, as methylation has been shown to cause both
positive and negative regulatory outcomes [40].
Our analysis of methylation profiles in ovarian and endometrial
tumors indicates value in characterizing tumors at the molecular
level. The methylator phenotype indicates an aberration in the
molecular function of enzymes regulating DNA methylation levels
and suggests that a molecule acting upstream of the candidate genes
is responsible for the cascade of events leading to tumor
development. Studies in hepatocellular carcinoma have identified
mutations in the beta-catenin gene in association with a methylator
phenotype. Mutations in beta-catenin are also common in
endometrial tumors [1], and suggest follow-up experiments to
assess a direct relationship to DNA methylation in endometrioid
tumors. Moreover, therapeutic strategies aimed at preventing
extensive methylation (such as 5-aza-29-deoxycytidine) should be
evaluated in the context of tumors with a methylator phenotype.
The consistency of the methylation profiles, despite independent
sample preparation and data collection for TCGA samples, was
used to validate and extend our results. These data show that
sample batch effects are minimal and do not disrupt data
consistency. Our data provide a foundation for future genomic
and genetic analyses of endometrial and serous tumors for
diagnostic and treatment applications. Notably, our results show
that methylation levels in serous tumors are less consistent than
endometrioid tumors, but increase and decrease in a target-
dependent way. In contrast endometrioid tumors show extensive
changes that are likely linked to a common upstream mechanism
gone awry.
Materials and Methods
Sample collection
Ovarian, endometrial and fallopian tube tissues were received
from the Magee-Womens Hospital Tissue Procurement Program
(Pittsburgh, PA). The tissues were snap frozen after surgery and
stored at 280uC. Genomic DNA was isolated using the Puregene
Blood Kit (Qiagen) following the manufacturer’s instructions.
DNA quality was assessed using a SmartSpec Plus spectropho-
tometer (BioRad, Hercules, CA).
Endometrial normal samples
Tissue samples were provided by the Cooperative Human
Tissue Network, which is funded by the National Cancer Institute.
Samples are from post-menopausal individuals with atrophic
endometrium and were obtained from routine hysterectomy or
pelvic resection for non-endometrial cancers. DNA was isolated
following the protocol of Trizol reagent (Invitrogen).
The use of human subject material was approved by the
University of Pittsburgh and the Office of Human Subjects
Research at the NIH.
TCGA data
TCGA data were downloaded at the time of this analysis from
the data portal (http://tcga-data.nci.nih.gov/tcga/dataAccess
Table 4. Gene ontology analysis, genes with differential methylation.
Molecular Function Gene Count
Total
Genes P-value Overlapping Gene set
GO:0005515 – protein binding 29 9005 0.00129 AHR APC CBFB CCT6A CDC47 DCC DNAJC14
EDG4 FGF22 GSTP1 HTATIP2 IL6 INSL4 KPNA1
LUC7L M-RIP MAP2K2 MAPK15 MYH1 NFS1
PARP3 PCDHGA12 PDPK1 PRAME RB1 S100A8
STRN3 UNC5CL WBP11
GO:0045786 – negative regulation of progression
through cell cycle
5 225 0.00486 AIFL APC DCC HTATIP2 RB1
GO:0007049 – cell cycle 8 839 0.00527 AHR AIFL APC DCC HTATIP2 RB1 STRN3
TXN14A
GO:0006954 –inflammatory response 6 291 0.0016 AIFL C1QC CYP4F11 IL6 PTAFR S100A8
GO:0009611 – response to wounding 6 423 0.00527 AIFL C1QC CYP4F11 IL6 PTAFR S100A8
GO:0006950 – response to stress 9 1222 0.0083 AHR AIFL APC C1QC CYP4F11 IL6 PARP3 PTAFR
S100A8
Uses Benjamini-Hochberg multiple testing correction.
doi:10.1371/journal.pone.0032941.t004
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Matrix.htm). Data from the same batch contained unmatched
serous tumors and normal fallopian tube samples. Normals:
TCGA-01-0639-11A-01D-0383-05, TCGA-01-0631-11A-01D-0383-
05, TCGA-01-0642-11A-02D-0383-05, TCGA-01-0628-11A-01D-
0383-05, TCGA-01-0637-11A-01D-0383-05, TCGA-01-0633-11A-
01D-0383-05, TCGA-01-0630-11A-01D-0383-05, TCGA-01-0636-
11A-01D-0383-05. Tumors: TCGA-09-0367-01A-01D-0359-05,
TCGA-09-0365-01A-02D-0359-05, TCGA-09-0366-01A-01D-0359-
05, TCGA-09-0369-01A-01D-0359-05.
DNA preparation
DNA was treated with bisulfite according to the protocol of
Zymo Research (Irvine, CA), with slight modification. One half
microgram of DNA was used for each conversion reaction. The
hybridization reaction was performed according to the Human-
Methylation27 Illumina BeadChip protocol and scanned using an
Illumina iScan System.
Methylation analysis
Experimental confidence levels were recorded as p-value
estimates for each methylation ratio measurement; all readings
with a corresponding p-value .0.05 were censored. These low-
confidence values were not uniformly distributed in the data,
therefore a few loci had an unusually large number of exclusions;
we chose to completely eliminate from consideration any probe
location at which values for ten or more samples were unavailable.
This step eliminated 61 loci.
Supervised analysis
We performed a comparison between normal fallopian tube
(control) and ovarian serous tumors. We excluded probes with
poor quality control metrics from the Illumina analysis software
(61 probes), and probes that had high variability within the control
samples (those with variance in the top 5%, 1,379 probes). We also
censored all data from the X and Y chromosomes (1,092 probes).
Some overlap in these sets resulted in eliminating a total of
2,489 loci. Differential analysis by Wilcoxon summed-rank test
was performed with the R function wilcox.test, followed by
Bonferroni correction for the 25,102 loci tested.
Clustering
Unsupervised clustering was performed in R. To select a subset
of loci to use, all primary samples were pooled, and the loci were
ranked by sample variance. The number of probes considered was
determined empirically, based on bootstrap support for clustering
results obtained for data sets of 50, 100, 250, or 500 probes. Based
on apparent stability of results with 250 or more probes, the top
500 probes were used for all clustering analyses. Model-based top-
down clustering was conducted with the b-mixture model
described in Houseman, 2008 [33]. K-means analysis was done
with the kmeans function, using within-group sum-of-squares to
select the number of clusters. Hierarchical clustering analysis used
the pvclust package, with the average and complete linkage
methods, and the Euclidean, Manhattan, and correlation distance
metrics.
To create a classifier from the clustering results, a beta
distribution was estimated for each of the 500 loci used for
clustering. These distributions were estimated separately for each
of four groups of samples: the endometrioid-type tumor cluster,
the serous-type tumor cluster, the control-type cluster, and a
cluster including both the control-type and serous-type tumor
samples. These groupings allowed a nested binary decision first
between endometrioid-type and all other samples, and then a
second division between the serous tumor and control clusters.
The test metric was calculated as the log of the ratio of probability
densities at the observed methylation level for the new sample,
summed over all 500 loci.
Differential analysis
In a pairwise comparison of a tumor cluster versus the control-
type cluster, we selected cases showing consistent signal in the
controls and alteration in the tumors. We again excluded probes
with poor quality, high variability in controls, and sex chromo-
some location; we also excluded all probes used in clustering for
the definition of classes (total: 2812). Differential analysis was again
done with Wilcoxon summed-rank test, correction for 24,766
independent tests.
Validation of differential methylation
For each probe in the set of differentially methylated sites, a
threshold was chosen that maximized the discrimination between
the previously identified control and serous clusters, minimizing
the total number of classification errors (false positives and false
negatives). 25 additional samples from ovarian serous tumors were
analyzed for DNA methylation as described above, and were
assessed for which group they were classified with at each of the
differential sites.
Supporting Information
Figure S1 Comparison of methylation intensity plots
from independent replicates and samples. Technical
replicates of methylation signals in normal fallopian tube,
endometrial tumors or ovarian metastases from primary endome-
trial samples, with best linear fit.
(TIF)
Figure S2 Clustering results for hierarchical and non-
hierarchical methods. At top, the tree shows the result of top-
down partitioning under a beta-mixture model. Below, the six
trees show results of hierarchical clustering under either complete
linkage (middle row) or average linkage (bottom row), for each of 3
distance metrics. For each method, color bocks beneath the tree
show the correspondence to the consensus clusters, with the
control-type cluster in blue, the serous-type cluster in black, and
the endometrioid cluster in red. For hierarchical methods, black
dots on tree nodes indicate $95% confidence in that grouping
under bootstrap analysis.
(EPS)
Figure S3 Box plot graph of differentially methylated
loci. Each differentially methylated gene, listed from top to
bottom by p-value is represented by a box plot for the methylation
in the control cluster (black) and the methylation in the serous
tumor cluster (red).
(EPS)
Figure S4 IPA network for Cell Cycle and Cell Mor-
phology. Differentially methylated genes participating in the
network are colored red with increasing intensity representing
smaller p-values. Shapes of molecules indicate distinct molecular
functions. Arrows represent direct and indirect interactions.
Designations for biomarkers are highlighted in green.
(TIFF)
Figure S5 IPA network for Inflammatory Response.
Differentially methylated genes participating in the network are
colored red with increasing intensity representing smaller p-values.
Shapes of molecules indicate distinct molecular functions. Arrows
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represent direct and indirect interactions. Designations for
biomarkers are highlighted in green.
(TIFF)
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